Australia markets open in 5 hours 11 minutes

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.6100-0.0400 (-2.42%)
As of 02:34PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.6500
Open1.6500
Bid1.6100 x 900
Ask1.6300 x 1000
Day's range1.6020 - 1.6997
52-week range1.2500 - 22.7400
Volume65,350
Avg. volume248,361
Market cap145.87M
Beta (5Y monthly)1.25
PE ratio (TTM)N/A
EPS (TTM)-0.9010
Earnings date22 Aug 2022 - 26 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.77
  • GlobeNewswire

    Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day

    BEIJING, June 16, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in the virtual Goldman Sachs Healthcare Corporate Day. Genetron’s management team, Sizhen Wang, co-founder and Chief Executive Officer and Evan

  • GlobeNewswire

    Genetron Health Receives CAP Accreditation for its Maryland Laboratory

    BEIJING, June 15, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced College of American Pathologists (CAP) Accreditation for its laboratory in Maryland, U.S. CAP Accreditation is designed to help laboratories maintain the accuracy of test results and

  • GlobeNewswire

    Genetron Health Reports Unaudited First Quarter 2022 Financial Results

    BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the f